Effects of Compound Active Peptides on Protecting Liver and Intestinal Epithelial Cells from Damages and Preventing Hyperglycemia
Table 3
Design of the combined dosing and descending dosing.
Groups
Treatment process
CG
Control group with normal saline for 31 d
MG
Model group with normal saline for 31 d
GT
Glibenclamide treatment (10 mg/kg BW/d) for 31 d
GAP
GT plus CAP (1.6 g/kg BW/d) added for the posterior 17 d
GLDP
GT plus LDP (0.4 g/kg BW/d) added for the posterior 17 d
TCD
GT plus (CAP+LDP) added for the posterior 17 d
DMG
GT for 21 d, decreased by 1 mg/kg BW/d for 7 d, and then kept at 3 mg/kg BW/d for 3 d
APG
DMG plus CAP added for the posterior 17 d
LDG
DMG plus LDP added for the posterior 17 d
ALG
DMG plus (CAP+LDP) added for the posterior 17 d
Note: except for the control group, diabetes model mice were used in the other groups. CAP: compound active peptide; LDP: Liuweidihuang pills (Chinese medicine).
